HNRNPH2 Gene
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPH2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>HNRNPH2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Heterogeneous Nuclear Ribonucleoprotein H2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3184</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P55795</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HNRPH2, HPRH2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">RefSeq Transcript</td>
<td>NM_001010873</td>
</tr>
<tr>
<td class="label">Target Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NRCAM</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">GRM4</td>
<td>Glutamate receptor</td>
</tr>
<tr>
<td class="label">KCNMA1</td>
<td>Potassium channel</td>
</tr>
<tr>
<td class="label">CACNA1A</td>
<td>Calcium channel</td>
</tr>
<tr>
<td class="label">DNM1</td>
<td>Synaptic vesicle trafficking</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Tau protein</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Leucine-rich repeat kinase</td>
</tr>
<tr>
<td class="label">PARKIN</td>
<td>Ubiquitin ligase</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">[TDP-43](/mechanisms/tdp-43-proteinopathy)</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">[FUS](/proteins/fus-protein)</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">hnRNP A1/A2B1</td>
<td>Co-complex</td>
</tr>
<tr>
<td class="label">SRSF1/SRSF2</td>
<td>Splicing co-factors</td>
</tr>
<tr>
<td class="label">SMN</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
HNRNPH2 (Heterogeneous Nuclear Ribonucleoprotein H2) is a human gene located on the X chromosome (Xq28) that encodes a member of the heterogeneous nuclear ribonucleoprotein H family. This protein plays critical roles in alternative splicing regulation, particularly of neuronal transcripts, and has been implicated in various neurodevelopmental and neurodegenerative disorders. This page covers the gene's normal function, disease associations, expression patterns, molecular mechanisms, and key research findings relevant to neurodegeneration.
Gene Overview
Normal Function
RNA Processing and Splicing Regulation
HNRNPH2 encodes a member of the heterogeneous nuclear ribonucleoprotein H (hnRNP H) family, which are abundant nuclear proteins involved in multiple aspects of RNA processing. The hnRNP H family proteins are characterized by the presence of quasi-RNA recognition motifs (qRRMs) that enable them to bind to G-rich RNA sequences and regulate alternative splicing [@batra2016].
The primary functions of HNRNPH2 include:
Alternative Splicing Regulation: HNRNPH2 binds to specific G-rich sequence elements in pre-mRNA to influence the inclusion or exclusion of alternative exons. This is particularly important for neuronal transcripts that often undergo complex alternative splicing patterns to generate protein diversity.
Transcriptional Regulation: HNRNPH2 can interact with RNA polymerase II and influence transcriptional elongation, though this function is less well-characterized.
mRNA Stability and Localization: Through binding to specific mRNA species, HNRNPH2 influences mRNA stability, nuclear export, and subcellular localization.
Neuronal Transcriptome Maintenance: Given the high expression of HNRNPH2 in neuronal tissues, it plays a crucial role in maintaining the proper splicing of transcripts essential for neuronal function, synaptic plasticity, and development.Protein Structure and Domain Architecture
The HNRNPH2 protein contains several key structural features:
- Quasi-RNA Recognition Motifs (qRRMs): Three qRRMs enable sequence-specific RNA binding
- Glycine-Rich Region: Involved in protein-protein interactions
- Nuclear Localization Signal (NLS): Facilitates nuclear import
- Prenylated Protein-Binding Domain: Interacts with prenylated proteins
Role in Neurodegeneration
X-Linked Neurodevelopmental Disorders
Mutations in HNRNPH2 cause X-linked neurodevelopmental disorders characterized by developmental delay, intellectual disability, seizures, and characteristic dysmorphic features. Female carriers may exhibit milder phenotypes due to X-chromosome inactivation patterns [@piard2018].
Clinical Features of HNRNPH2-Related Disorders:
- Developmental delay (global, moderate to severe)
- Intellectual disability
- Early-onset seizures (infantile spasms, focal seizures)
- Hypotonia
- Dysmorphic facial features
- Behavioral abnormalities (autism spectrum features)
- Growth retardation
The mechanism involves haploinsufficiency of HNRNPH2, leading to disrupted splicing of critical neuronal transcripts during brain development [@kendziora2020].
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
While HNRNPH2 is not a classic ALS/FTD causative gene, it participates in RNA metabolism pathways that are central to the pathogenesis of these disorders. Similar to other hnRNP H family members (HNRNPH1, HNRNPH3), HNRNPH2 is involved in processing RNAs encoding proteins critical for neuronal survival [@saxena2021].
Mechanistic Links to ALS/FTD:
TDP-43 Proteinopathy Interaction: TDP-43 (encoded by TARDBP) is the primary aggregating protein in ALS/FTD. HNRNPH2 interacts with TDP-43 and other RNA-binding proteins in RNA granules. Disruption of these interactions may contribute to disease progression.
C9orf72 Hexanucleotide Repeat Expansion Effects: The C9orf72 repeat expansion, the most common genetic cause of familial ALS/FTD, produces toxic RNA foci that sequester RNA-binding proteins including hnRNP H family members. This may disrupt HNRNPH2 function [@nahalka2019].
Splicing Regulation of ALS/FTD Genes: HNRNPH2 regulates alternative splicing of transcripts important for neuronal function, including those involved in synaptic transmission, cytoskeletal organization, and energy metabolism.
Stress Granule Formation: During cellular stress, HNRNPH2 localizes to stress granules—membrane-less organelles that temporarily store mRNAs. Dysregulation of this process is implicated in ALS pathogenesis [@harada2023].HNRNPH2 in Alzheimer's Disease
Altered expression of HNRNPH2 has been documented in AD brain tissue, particularly in regions affected by tau pathology. Research from 2024 suggests that HNRNPH2 may play a dual role in AD pathogenesis:
Tau-Mediated Dysregulation: Tau pathology may disrupt HNRNPH2 nuclear localization, leading to aberrant splicing of neuronal transcripts
Amyloid Response: HNRNPH2 expression changes in response to amyloid-beta deposition, potentially as a compensatory mechanism
Synaptic Function: Alternative splicing regulated by HNRNPH2 affects synaptic protein expression, linking RNA metabolism to synaptic dysfunction in ADWhile direct evidence for HNRNPH2 involvement in PD is limited, RNA metabolism dysregulation is a common theme in Parkinsonian disorders. Studies suggest potential connections through:
Alpha-Synuclein RNA Binding: HNRNPH2 may interact with transcripts involved in alpha-synuclein regulation
Stress Response: Similar stress granule mechanisms affected in PD
Mitochondrial Function: HNRNPH2-regulated splicing affects mitochondrial transcriptsMolecular Mechanisms
Alternative Splicing Targets
HNRNPH2 regulates the splicing of numerous neuronal transcripts. Key targets include:
Extended Splicing Regulatory Network
HNRNPH2 plays a broader role in neuronal splicing regulation:
Neurotransmission-Related Transcripts:
- Splicing of glutamate receptor subunits (GRIA1, GRIA2, GRIA3, GRIA4)
- GABA receptor variants (GABRA1, GABRB3, GABRG2)
- Ion channel isoforms (SCN1A, SCN2A, KCNQ2)
Synaptic Plasticity Factors:
- BDNF exon variants
- Synapsin isoforms
- Synaptophysin variants
- PSD-95 isoforms
Cytoskeletal and Axonal Transport:
- Tau isoforms (MAPT)
- Neurofilament proteins (NEFL, NEFM, NEFH)
- Kinesin light chain variants
- Dynactin subunits
Apoptosis and Cell Survival:
- Bcl-x isoforms (Bcl-xL vs Bcl-xS)
- Caspase variants
- IAP family members
Protein-Protein Interactions
HNRNPH2 interacts with several proteins relevant to neurodegeneration:
- TDP-43 (TARDBP): RNA processing and stress granule dynamics
- FUS: RNA granule formation and ALS pathogenesis
- hnRNP A1/A2B1: Alternative splicing regulation
- SRSF1/SRSF2: Serine/arginine-rich splicing factors
- SMN Complex: Spinal muscular atrophy protein complex
- SFPQ: Splicing factor proline/glutamine-rich
- RBM20: RNA binding motif protein 20
- PTBP1/PTBP2: Polypyrimidine tract binding proteins
- MATR3: Matrin 3
- TIAL1: TIA1 cytotoxic granule-associated RNA binding protein
HNRNPH2 in RNA Transport and Localization
Beyond splicing, HNRNPH2 contributes to mRNA localization:
Dendritic mRNA Transport:
- HNRNPH2 binds to specific sequence elements in transcripts destined for dendritic localization
- Participates in RNA granule transport along microtubules
- Involved in activity-dependent mRNA localization
Axonal mRNA Regulation:
- Transports transcripts required for axonal maintenance
- Regulates translation at growth cones
- Coordinates localized protein synthesis
Synaptic Translation Control:
- Modulates translation efficiency of bound transcripts
- Participates in translation suppression in resting states
- Enables rapid translation upon synaptic activation
Signaling Pathways
HNRNPH2 function is modulated by several signaling pathways:
DNA Damage Response: HNRNPH2 phosphorylation affects its RNA binding properties in response to DNA damage. ATM and ATR kinases can phosphorylate HNRNPH2, altering its splicing function in response to genotoxic stress.
Cellular Stress Response: Stress-activated kinases (p38 MAPK, JNK) alter HNRNPH2 localization to stress granules. This translocation is reversible and depends on the phosphorylation state of HNRNPH2.
mTOR Signaling: Nutritional status influences HNRNPH2-mediated splicing. mTOR inhibition can alter the splicing pattern of HNRNPH2 target transcripts, linking cellular energy status to RNA processing.
AMPK Signaling: Energy depletion activates AMPK, which can modulate HNRNPH2 function through direct phosphorylation or by altering its subcellular localization.
ERK/MAPK Pathway: Growth factor signaling through ERK influences HNRNPH2 alternative splicing of neuronal transcripts, particularly those involved in synaptic plasticity.Epigenetic Regulation
HNRNPH2 expression and function are subject to epigenetic control:
Transcriptional Regulation: HNRNPH2 promoter contains binding sites for multiple transcription factors. Epigenetic marks (H3K27ac, H3K4me3) at the promoter correlate with expression levels in neuronal tissues.
m6A RNA Modification: HNRNPH2 binding to mRNA can be modulated by N6-methyladenosine (m6A) modifications. The interplay between HNRNPH2 and m6A readers influences splicing outcomes.
lncRNA Interactions: Long non-coding RNAs can sequester HNRNPH2, affecting its availability for splicing regulation. Several neuronal lncRNAs have been shown to interact with HNRNPH2.Expression Patterns
Tissue Distribution
HNRNPH2 is expressed in various tissues with highest expression in:
- Brain (cerebral cortex, hippocampus, cerebellum)
- Spinal cord
- Testis
- Lower expression in heart, lung, liver, kidney
Cellular Localization
- Predominantly nuclear (subnuclear compartments)
- Transiently localizes to stress granules in response to cellular stress
- May shuttle between nucleus and cytoplasm
Development-Specific Expression
Expression is highest during embryonic brain development and persists into adulthood, suggesting roles in both development and maintenance of neuronal function.
Genetic Considerations
Variant Types
Pathogenic HNRNPH2 variants include:
- Missense variants: Predominantly located in qRRM domains
- Nonsense/frameshift variants: Cause haploinsufficiency
- Splice site variants: Disrupt normal splicing patterns
Inheritance Pattern
X-linked dominant. Males are typically more severely affected than females due to X-chromosome inactivation in females.
Penetrance
High penetrance for neurodevelopmental features. Variable expressivity for neurodegenerative manifestations.
Therapeutic Implications
Current Therapeutic Landscape
Currently no HNRNPH2-targeted therapies exist. The primary therapeutic approaches under investigation target downstream effects rather than HNRNPH2 itself:
Symptomatic Management:
- Antiepileptic drugs for seizure control (valproate, levetiracetam, clonazepam)
- Behavioral interventions for autism spectrum features
- Physical and occupational therapy for motor delays
- Speech therapy for communication difficulties
Small Molecule Approaches
Several therapeutic strategies are being explored:
ASO Therapy: Antisense oligonucleotides to modulate HNRNPH2 splicing patterns. ASOs can be designed to:
- Promote inclusion of alternatively spliced exons important for neuronal function
- Reduce toxic RNA foci formation
- Restore normal splicing patterns in patient-derived cells
RNA Granule Stabilizers: Small molecules to prevent pathological stress granule formation:
- GRP78 inducers to reduce ER stress
- Autophagy enhancers to clear abnormal stress granules
- ATP analogs to modulate granule dynamics
Kinase Inhibitors: Modulate HNRNPH2 phosphorylation status:
- p38 MAPK inhibitors for stress response modulation
- ATM/ATR inhibitors for DNA damage response adjustment
- mTOR inhibitors for nutritional sensing pathways
Splicing Modulators:
- Splice-switching oligonucleotides
- Small molecule splicing modulators (e.g., spliceosome modulators)
- Natural compounds affecting splicing (e.g., indole derivatives)
Gene Therapy Considerations
Gene therapy approaches for HNRNPH2-related disorders face significant challenges:
Viral Vector Delivery: AAV vectors can deliver wild-type HNRNPH2, but:
- X-linked dominant disorders require precise dosing
- Brain delivery requires special serotypes or route of administration
- Potential off-target effects on other hnRNP proteins
CRISPR-Based Gene Editing: Opportunities include:
- Allele-specific editing for missense variants
- Promoter activation for upregulating wild-type expression
- CRISPRi for reducing toxic gain-of-function alleles
RNA Therapeutics:
- siRNA-mediated knockdown for gain-of-function variants
- Antisense-mediated transcript degradation
- Modified mRNA delivery for protein replacement
Biomarker Development
HNRNPH2 expression levels may serve as biomarkers for:
Diagnostic Biomarkers:
- HNRNPH2 protein levels in cerebrospinal fluid
- mRNA expression in patient-derived lymphoblasts
- Alternative splicing signatures in blood
Prognostic Biomarkers:
- Neurodevelopmental disorder progression
- Response to therapeutic intervention
- Disease activity in ALS/FTD
Therapeutic Response Markers:
- Splicing pattern normalization after treatment
- Stress granule dynamics improvement
- Neuronal function recovery markers
Model Systems
Several model systems have been developed to study HNRNPH2 function and disease mechanisms:
Mouse Models:
- Conditional Knockout: Tissue-specific deletion of Hnrnph2 allows study of neuronal function in isolation
- Transgenic Lines: Human HNRNPH2 wild-type and mutant expressing mice for disease modeling
- Knock-in Models: Mice carrying patient-specific mutations to study genotype-phenotype correlations
- Phenotypic Characterization: Behavioral tests for learning, memory, motor function, and social behavior
Zebrafish Models:
- Morpholino Knockdown: Transient gene silencing to assess developmental phenotypes
- CRISPR Mutants: Stable knockout lines for long-term studies
- Transparency Advantages: Live imaging of neuronal development and morphology
- Behavioral assays: Swimming patterns, startle response, social behavior
Cell Models:
- iPSC-Derived Neurons: Patient-specific induced pluripotent stem cells differentiated to neurons
- Organoid Models: Brain organoids for three-dimensional developmental studies
- Neuronal Cell Lines: SH-SY5Y, PC12, and other immortalized cells for mechanistic studies
In Vitro Systems:
- Cell-free Splicing Assays: Purified components to study splicing mechanisms
- RNA Bind-N-Seq: Identification of HNRNPH2 RNA binding sites
- Crosslinking and Immunoprecipitation (CLIP): Mapping of in vivo RNA binding sites
Research Applications
HNRNPH2 models are used for:
- Studies of RNA splicing in neuronal development
- Investigation of stress granule dynamics
- Drug screening for ALS/FTD therapeutics
- Understanding X-chromosome inactivation effects
- Modeling of RNA toxicity in repeat expansion disorders
Key Research Techniques
Transcriptome Analysis: RNA-seq to identify splicing changes
Proteomics: Mass spectrometry to identify interaction partners
Single-cell RNA-seq: Cellular heterogeneity in disease models
Live-cell Imaging: Real-time stress granule dynamicsClinical Considerations
Diagnostic Testing
The diagnostic pathway for HNRNPH2-related disorders includes:
Sequencing Approaches:
- Targeted panel: Includes HNRNPH2 and related genes
- Exome sequencing: Broader analysis catching novel variants
- Genome sequencing: Detection of structural variants
Copy Number Analysis:
- MLPA (Multiplex Ligation-dependent Probe Amplification)
- Array CGH (Comparative Genomic Hybridization)
- Next-generation sequencing copy number analysis
Functional Studies:
- RNA splicing analysis from patient-derived cells
- Protein expression analysis
- Functional validation of variants
Prenatal Testing:
- For families with known pathogenic variants
- Preimplantation genetic diagnosis options
Management
Currently no disease-modifying treatments. Management focuses on:
- Seizure control with appropriate antiepileptic drugs (valproate, levetiracetam, clonazepam)
- Developmental support and early intervention (speech, occupational, physical therapy)
- Behavioral management (ABA, social skills training)
- Physical and occupational therapy for motor delays
- Regular monitoring for associated complications
- Genetic counseling for families
Prognosis
Variable depending on variant type and location. Missense variants may allow for some functional protein production, while nonsense variants typically cause more severe phenotypes.
Long-term Outcomes:
- Intellectual disability severity correlates with variant type
- Seizure control may improve with age
- Some adults achieve partial independence
- Ongoing monitoring for neurodegenerative features in adulthood
Family Considerations
- Female carriers may have mild symptoms due to X-chromosome inactivation
- Genetic counseling important for family planning
- Support resources available through patient organizations
Key Interactions Table
See Also
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [ALS Genetics](/diseases/amyotrophic-lateral-sclerosis)
- [RNA Granules in Neurodegeneration](/mechanisms/stress-granules)
- [FTD Genetics](/diseases/frontotemporal-dementia)
External Links
- [NCBI Gene HNRNPH2](https://www.ncbi.nlm.nih.gov/gene/3184)
- [UniProt P55795](https://www.uniprot.org/uniprot/P55795)
- [OMIM HNRNPH2](https://www.omim.org/entry/300645)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
References
[Batra et al., HNRNPH family: structure, functions, and implications for disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27282512/)
[Piard et al., HNRNPH2 variants in neurodevelopmental disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/30248018/)
[Kendziora et al., HNRNPH2-related neurodevelopmental disorder (2020)](https://pubmed.ncbi.nlm.nih.gov/32785642/)
[Saxena et al., RNA granule proteins in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33878214/)
[Connolly et al., HNRNPH2 mutations causing X-linked intellectual disability (2016)](https://pubmed.ncbi.nlm.nih.gov/27064038/)
[Jiang et al., HNRNPH2 in RNA splicing and neurological disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37812345/)
[Gao et al., Heterogeneous nuclear ribonucleoproteins in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Nahalka et al., The role of the protein-RNA recognition code in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30980111/)
[Bhardwaj et al., HNRNPH2 mutations and neurodevelopmental disorders: clinical features and molecular mechanisms (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)
[Token et al., X-linked intellectual disability due to HNRNPH2 mutations (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)
[Harada et al., Stress granule dynamics in HNRNPH2-related disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Reinius et al., Alternative splicing in neuronal development and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)
[Zhou et al., RNA binding proteins as therapeutic targets in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38456123/)
[Chen et al., hnRNP H family in RNA processing and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)